Development of the new cerebral infarction therapy by HSP27 protein

点击翻译按钮获取中文摘要

We examined the method of producing activated recombinant HSP27 for future clinical application of the new cerebral infarction treatment by HSP27 protein. Dephosphorylated recombinant HSP27 which made and purified from Escherichia coli had low brain protection activity. The recombinant HSP27 protein was phosphorylated. Phosphorylated recombinant HSP27 had brain protection. Infarct volume was reduced by 52% in stroke model mice when phosphorylated recombinant HSP27 was administered. We developed the method of mass-producing activated phosphoryled recombinant HSP27 in vitro.